Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Head & Neck 1Gastrointestinal 1

Conditions

Head and Neck Neoplasms 1284Squamous Cell Carcinoma of Head and Neck 707Thyroid Neoplasms 297Carcinoma, Non-Small-Cell Lung 180Mouth Neoplasms 177Neoplasms 173Breast Neoplasms 172Lung Neoplasms 152Salivary Gland Neoplasms 143Oropharyngeal Neoplasms 132Nasopharyngeal Carcinoma 128Melanoma 117Carcinoma, Squamous Cell 116Colorectal Neoplasms 112Laryngeal Neoplasms 108Ovarian Neoplasms 102Esophageal Neoplasms 100Nasopharyngeal Neoplasms 96Prostatic Neoplasms 92Pancreatic Neoplasms 92Stomach Neoplasms 88Uterine Cervical Neoplasms 86Neoplasm Metastasis 86Thyroid Cancer, Papillary 78Carcinoma, Renal Cell 78Urinary Bladder Neoplasms 74Thyroid Nodule 68Sarcoma 65Colonic Neoplasms 63Small Cell Lung Carcinoma 62

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Disorders of Sex Development × Head & Neck × Clear all
NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Novartis

Phase 2 Completed
122 enrolled 28 charts
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡